Lysosomal GBA1 Enhancement via Glucosylceramide Reduction
🧪 Overview
GBA1 mutations increase α-synuclein aggregation risk through glucosylceramide accumulation. Enhancement of GCase activity via chaperone therapy (ambroxol) or substrate reduction (GCS inhibitors) represents the strongest therapeutic approach with active clinical trials, favorable safety profile, and FDA orphan designation for genetically-defined PD subtype.
🧬 Mechanism
⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — GBA1
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for GBA1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
▸Metadataorigin_type: debate_synthesizer
| origin_type | debate_synthesizer |
| target_gene | GBA1 |
| _schema_version | 1 |
| composite_score | 0.8 |